260 related articles for article (PubMed ID: 33506674)
1. Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91.
Hanafi M; Chen X; Neamati N
J Med Chem; 2021 Feb; 64(3):1626-1648. PubMed ID: 33506674
[TBL] [Abstract][Full Text] [Related]
2. Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated Cancer Cell Death.
Froeling FEM; Swamynathan MM; Deschênes A; Chio IIC; Brosnan E; Yao MA; Alagesan P; Lucito M; Li J; Chang AY; Trotman LC; Belleau P; Park Y; Rogoff HA; Watson JD; Tuveson DA
Clin Cancer Res; 2019 Dec; 25(23):7162-7174. PubMed ID: 31527169
[TBL] [Abstract][Full Text] [Related]
3. A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3).
Li C; Chen C; An Q; Yang T; Sang Z; Yang Y; Ju Y; Tong A; Luo Y
Eur J Med Chem; 2019 Jan; 162():543-554. PubMed ID: 30472602
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Tumor Cell-Tumor Microenvironment Component Interactions as Potential Predictors of Patient Response to Napabucasin.
Chang AY; Hsu E; Patel J; Li Y; Zhang M; Iguchi H; Rogoff HA
Mol Cancer Res; 2019 Jul; 17(7):1429-1434. PubMed ID: 31043490
[TBL] [Abstract][Full Text] [Related]
5. Zinc finger protein 91 (ZFP91) activates HIF-1α via NF-κB/p65 to promote proliferation and tumorigenesis of colon cancer.
Ma J; Mi C; Wang KS; Lee JJ; Jin X
Oncotarget; 2016 Jun; 7(24):36551-36562. PubMed ID: 27144516
[TBL] [Abstract][Full Text] [Related]
6. Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
Löcken H; Clamor C; Müller K
J Nat Prod; 2018 Jul; 81(7):1636-1644. PubMed ID: 30003778
[TBL] [Abstract][Full Text] [Related]
7. The Anticancer Effect of Napabucasin (BBI608), a Natural Naphthoquinone.
Shao Z; Wang H; Ren H; Sun Y; Chen X
Molecules; 2023 Jul; 28(15):. PubMed ID: 37570646
[TBL] [Abstract][Full Text] [Related]
8. STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells.
Liu Y; Peng X; Li H; Jiao W; Peng X; Shao J; Xu Y; Wang R; Wang W; Kong D
Recent Pat Anticancer Drug Discov; 2021; 16(3):350-362. PubMed ID: 33655847
[TBL] [Abstract][Full Text] [Related]
9. Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma.
Li X; Wei Y; Wei X
Cancer Lett; 2020 Oct; 491():146-161. PubMed ID: 32798587
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
Thulin MH; Määttä J; Linder A; Sterbova S; Ohlsson C; Damber JE; Widmark A; Persson E
Prostate; 2021 Jun; 81(8):452-462. PubMed ID: 33822400
[TBL] [Abstract][Full Text] [Related]
11. ZFP91: A Noncanonical NF-
Paschke L; Jopek K; Szyszka M; Tyczewska M; Ziolkowska A; Rucinski M; Malendowicz LK
Biomed Res Int; 2016; 2016():6963582. PubMed ID: 27975057
[TBL] [Abstract][Full Text] [Related]
12. New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation.
Wang X; Feng S; Fan J; Li X; Wen Q; Luo N
Biochem Pharmacol; 2016 Sep; 116():200-9. PubMed ID: 27473774
[TBL] [Abstract][Full Text] [Related]
13. Atypical E3 ligase ZFP91 promotes small-molecule-induced E2F2 transcription factor degradation for cancer therapy.
Liu TT; Yang H; Zhuo FF; Yang Z; Zhao MM; Guo Q; Liu Y; Liu D; Zeng KW; Tu PF
EBioMedicine; 2022 Dec; 86():104353. PubMed ID: 36375317
[TBL] [Abstract][Full Text] [Related]
14. LB-1 Exerts Antitumor Activity in Pancreatic Cancer by Inhibiting HIF-1α and Stat3 Signaling.
Niu F; Li Y; Lai FF; Ni L; Ji M; Jin J; Yang HZ; Wang C; Zhang DM; Chen XG
J Cell Physiol; 2015 Sep; 230(9):2212-23. PubMed ID: 25655308
[TBL] [Abstract][Full Text] [Related]
15. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells.
Han D; Yu T; Dong N; Wang B; Sun F; Jiang D
J Exp Clin Cancer Res; 2019 Jul; 38(1):289. PubMed ID: 31277685
[TBL] [Abstract][Full Text] [Related]
16. Molecular crosstalk between MUC1 and STAT3 influences the anti-proliferative effect of Napabucasin in epithelial cancers.
Bose M; Sanders A; Handa A; Vora A; Cardona MR; Brouwer C; Mukherjee P
Sci Rep; 2024 Feb; 14(1):3178. PubMed ID: 38326371
[TBL] [Abstract][Full Text] [Related]
17. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.
Hubbard JM; Grothey A
Drugs; 2017 Jul; 77(10):1091-1103. PubMed ID: 28573435
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.
Zhou H; Bai L; Xu R; Zhao Y; Chen J; McEachern D; Chinnaswamy K; Wen B; Dai L; Kumar P; Yang CY; Liu Z; Wang M; Liu L; Meagher JL; Yi H; Sun D; Stuckey JA; Wang S
J Med Chem; 2019 Dec; 62(24):11280-11300. PubMed ID: 31747516
[TBL] [Abstract][Full Text] [Related]
19. Thermal Proteome Profiling in Zebrafish Reveals Effects of Napabucasin on Retinoic Acid Metabolism.
Leijten NM; Bakker P; Spaink HP; den Hertog J; Lemeer S
Mol Cell Proteomics; 2021; 20():100033. PubMed ID: 33594990
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells.
Zuo D; Shogren KL; Zang J; Jewison DE; Waletzki BE; Miller AL; Okuno SH; Cai Z; Yaszemski MJ; Maran A
J Exp Clin Cancer Res; 2018 Oct; 37(1):244. PubMed ID: 30286779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]